Clinical Trial

Registry Platform Ovarian and Endometrial Cancer

Study acronym: SMARAGD
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-11-10; most recent amendment 2026-01-26.
Status change: Not Yet Recruiting → Recruiting 2021-12-01
Trial Details
NCT Number NCT05129969
Lead Sponsor iOMEDICO AG
Conditions Ovarian Cancer, Endometrial Cancer, Ovary Neoplasm, Endometrial Neoplasms, Carcinoma, Ovarian, Carcinoma, Neoplasm, Ovarian
Enrollment 1,975 participants
Start Date 2021-11-25
Primary Completion 2030-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-28